Cascination AG appears in FDA 510(k) records as the applicant for two devices decided in late 2026: OTOPLAN under K262080 and CAS-One IR under K261225. The company describes itself on its own website as a Swiss medical device company whose robotic and image-guided solutions support minimally invasive therapies in cancer treatment and hearing disorders. The filings identify the applicant by name and address; they do not establish corporate ownership, parentage or brand relationships beyond that. [1][2][4]
OTOPLAN and the otology filing
OTOPLAN was cleared as substantially equivalent under K262080, decided October 23, 2026, with a receipt date of June 22, 2026. The record lists product code QQE, regulation number 892.2050, Class II, and the device name as image management software for planning of otologic and neurotologic procedures, with radiology as the advisory committee. The applicant is recorded as Cascination AG at Steigerhubelstrasse 3, Bern, Switzerland. [1]
Cascination's website describes OTOPLAN as otological planning software producing patient-specific 3D inner ear reconstructions. A separate OTOPLAN page states that the latest version extends post-operative assessment to locate each electrode contact using CT images and plain X-rays, and that the product is exclusively distributed by MED-EL, with clinical support directed to MED-EL. These are publisher statements about the product, not FDA findings. [4][9]
CAS-One IR and the CT system filing
CAS-One IR was cleared under K261225, decided September 29, 2026, with the submission dated and received August 28, 2026. The clearance letter names the trade device CAS-One IR, regulation 21 CFR 892.1750, computed tomography x-ray system, Class II, product code JAK, and states that the device is substantially equivalent to a legally marketed predicate for the indications for use in the enclosure. The letter is addressed to Philip Frost as regulatory and clinical affairs specialist. [3]
The same letter states that the device has no patient contact. Cascination's website presents CAS-One IR under the heading Quality Ablation, described as supporting reproducible and standardized tumour treatments. The website places CAS-One IR and OTOPLAN alongside HEARO, described there as a robot for cochlear implantation, within a product range for oncology and otology. [3][4]
What the supplied filings cover
The supplied collection contains two linked 510(k) records, both with a substantially equivalent decision, and no recall records. That count reflects the filings retrieved as of the snapshot date and is not a measure of total company sales, total portfolio or safety performance. The smaller record sample likewise contains two substantially equivalent decisions, matching the full collection in this instance. [1][2]
The two records differ in scope. OTOPLAN is filed as software for planning otologic and neurotologic procedures under product code QQE, while CAS-One IR is filed as a computed tomography x-ray system under product code JAK. The clearance letter for CAS-One IR notes no patient contact, which distinguishes the filing scope from any clinical use description on the company website. [1][3]
Identity and attribution
FDA records identify Cascination AG as the applicant, with a Bern address given in the filing. That address is a filing address and does not by itself establish a headquarters location. The company's own website describes it as a Swiss medical device company with a mission to bring certainty to medical treatment outcomes, and describes its robotic and image-guided solutions as enabling reproducible and efficient interventions. [1][4]
Product descriptions, distribution arrangements and claims about surgical workflow come from Cascination's website and its OTOPLAN page, attributed there to the publisher. The FDA records establish the applicant name, device names, product codes, regulation numbers, decision dates and substantial equivalence determinations for the two filings described. No ownership structure, customer list, certification or commercial availability beyond these sources is documented here. [3][4][9]


